Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00435916 · ClinicalTrials.gov registry record · Phase 2
Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma
A Phase 2 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT00435916 is a Phase 2 study that has completed, run by Seagen. The registered enrollment target is 46 participants.
The verdict
NCT00435916, a Phase 2 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
This is a Phase II, open-label, multidose trial of SGN-40 designed to estimate objective response rate and assess toxicity in patients with relapsed DLBCL.
Interventions
- DRUG SGN-40
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2006-12 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00435916
The ClinicalTrials.gov registry entry for NCT00435916 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SGN-40 is the first listed.
NCT00435916 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00435916 about?
NCT00435916 is a clinical study titled "Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma". This is a Phase II, open-label, multidose trial of SGN-40 designed to estimate objective response rate and assess toxicity in patients with relapsed DLBCL.
What is the current status of trial NCT00435916?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2006-12. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00435916?
The interventions under investigation include: SGN-40 (DRUG).
Who is sponsoring clinical trial NCT00435916?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.